Apidra is a fast-acting insulin that controls blood sugar levels after meals in people with diabetes. This eMedTV page describes how to administer Apidra, lists side effects, and discusses how the drug can help treat type 1 or type 2 diabetes.
Some of the common side effects of Apidra can include low blood sugar and reactions at the injection site. This eMedTV segment also takes an in-depth look at some of the more serious Apidra side effects that require immediate medical attention.
This eMedTV segment explains why Apidra is used for treating type 1 or type 2 diabetes. This page further discusses Apidra uses, including how this rapid-acting insulin works to control blood sugar and its off-label use to treat gestational diabetes.
This selection from the eMedTV Web site explains the factors that may affect your Apidra dosage, such as other medications you are taking and other medical conditions you have. This page also lists tips on when and how to administer the injections.
This eMedTV page explores potential Apidra drug interactions with other medications, such as oral diabetes medicines, some antibiotics, and beta blockers. This page also explains how these interactions can cause dangerously low blood sugar levels.
This eMedTV page discusses several important Apidra warnings and precautions, such as the risk of dangerously low blood sugar levels. This page also explains what to tell your doctor before starting Apidra and describes who should not use it.
If you overdose on Apidra (insulin glulisine), seek immediate medical care. This portion of the eMedTV Web site describes possible effects of an Apidra overdose, including dangerously low blood sugar. This page also covers possible treatment options.
This eMedTV page explores the results of animal studies on Apidra (insulin glulisine) and pregnancy, explaining why the FDA has classified it as a pregnancy Category C drug. This page also covers why some doctors recommend Apidra during pregnancy.
This eMedTV page explains that it is probably safe to use Apidra (insulin glulisine) while breastfeeding, as the medicine would be destroyed in the infant's digestive tract. This page further explores the safety issues with Apidra and breastfeeding.
This part of the eMedTV archives discusses why there is currently no approved generic Apidra (insulin glulisine) available. This page also explains why 2018 is the earliest date a generic version could become available, if certain laws are changed.
| Referring Pages | Articles |
